3
Participants
Start Date
April 30, 2009
Primary Completion Date
August 31, 2010
Study Completion Date
October 31, 2010
Decitabine and Pegylated Interferon-Alfa 2B
Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
Nevada Cancer Institute, Las Vegas
Collaborators (1)
National Institutes of Health (NIH)
NIH
Schering-Plough
INDUSTRY
Nevada Cancer Institute
OTHER